Literature DB >> 27694315

Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion.

H C Diener1, R Bernstein2,3, K Butcher4, B Campbell5, G Cloud6, A Davalos7, S Davis8, J M Ferro9, M Grond10, D Krieger11,12, G Ntaios13, A Slowik14, E Touzé15.   

Abstract

Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.

Entities:  

Keywords:  Ischemic stroke; dabigatran; idarucizumab; rt-PA; thrombectomy; thrombolysis

Mesh：

Substances：

Year:  2016        PMID： 27694315     DOI： 10.1177/1747493016669849

Source DB:  PubMed          Journal:  Int J Stroke        ISSN： 1747-4930            Impact factor:   5.266


  20 in total

1.  Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.

Authors:  Felix C Ng; James Bice; Anne Rodda; Matthew Lee-Archer; Douglas E Crompton
Journal:  J Neurol       Date:  2017-02-06       Impact factor: 4.849

Review 2.  [Appropriate treatment of acute stroke at all times and in all places : Organizational concepts and new approaches].

Authors:  J E Weber; H J Audebert
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

Review 3.  Patients on NOACs in the Emergency Room.

Authors:  Stefan T Gerner; Hagen B Huttner
Journal:  Curr Neurol Neurosci Rep       Date:  2019-05-29       Impact factor: 5.081

4.  Thrombolysis in Acute Ischemic Stroke after Idarucizumab for Dabigatran Etexilate Reversal in Elderly: A Case Report.

Authors:  Antonio Baule; Federico Cabigiosu; Bastianina Zanda; Alessandra Sanna; Claudia Mongili; Antonio Manca
Journal:  J Vasc Interv Neurol       Date:  2018-11

Review 5.  [Direct oral anticoagulants and acute stroke : Insights into translational research studies].

Authors:  C Foerch; J H Schäfer; W Pfeilschifter; F Bohmann
Journal:  Nervenarzt       Date:  2017-06       Impact factor: 1.214

6.  Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients.

Authors:  Maren Hieber; Heiko Hollasch; Dorothee Heck; Mirjam Mächtel; Ulrich Geisen; Wolf-Dirk Niesen; Jochen Brich; Andreas Harloff
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

7.  European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke.

Authors:  Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc
Journal:  Eur Stroke J       Date:  2021-02-19

8.  Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature.

Authors:  Senta Frol; Dimitrios Sagris; Janja Pretnar Oblak; Mišo Šabovič; George Ntaios
Journal:  Front Neurol       Date:  2021-06-03       Impact factor: 4.003

9.  A case report of parenchymal hematoma after intravenous thrombolysis in a rivaroxaban-treated patient: Is it a true rivaroxaban hemorrhagic complication?

Authors:  Eugenia Rota; Gianluca Bruzzone; Sergio Agosti; Roberto Pastorino; Nicola Morelli
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 10.  Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.

Authors:  Chen Jin; Ryan J Huang; Eric D Peterson; Daniel T Laskowitz; Adrian F Hernandez; Jerome J Federspiel; Lee H Schwamm; Deepak L Bhatt; Eric E Smith; Gregg C Fonarow; Ying Xian
Journal:  Stroke       Date:  2018-09       Impact factor: 7.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.